ZJAMP.(SZ:002758)2018-10-26 16:00Financial Performance - Operating revenue for the reporting period was ¥388,839,109.05, representing an increase of 11.97% compared to the same period last year[8]. - Net profit attributable to shareholders of the listed company was ¥7,147,454.35, a decrease of 32.35% year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥6,393,122.90, down 43.25% compared to the same period last year[8]. - The basic earnings per share was ¥0.03, a decrease of 40.00% year-on-year[8]. - The weighted average return on net assets was 1.12%, down 0.74% compared to the same period last year[8]. - The estimated net profit for 2018 is projected to decrease by 30.00% to 0.00%, with a range of ¥2,944.47 to ¥4,206.38 million, influenced by industry policies and market competition[22]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,459,721,268.51, an increase of 20.30% compared to the end of the previous year[8]. - Net assets attributable to shareholders of the listed company amounted to ¥642,075,254.02, reflecting a growth of 10.64% year-on-year[8]. - Total current assets rose by 30.88% to ¥991,120,321.94, mainly driven by funds received from the issuance of convertible bonds[17]. - The total liabilities increased significantly by 1482.43% to ¥179,549,601.01, primarily due to the issuance of convertible bonds[17]. - The company’s fixed assets grew by 37.68% to ¥327,552,388.06, mainly from the completion of construction projects[17]. Cash Flow - The net cash flow from operating activities was -¥4,763,516.03, indicating a significant decline of 88.89%[8]. - The net cash flow from operating activities improved by 88.89%, amounting to -¥4,763,516.03, due to increased cash receipts from sales[18]. - The company's cash and cash equivalents increased by 464.81%, reaching ¥196,363,499.74, primarily due to funds raised from the issuance of convertible bonds[18]. Expenses - The company reported a 203.89% increase in financial expenses, totaling ¥11,536,181.94, attributed to increased bank loans and interest expenses from convertible bonds[17]. - Research and development expenses increased by 47.36% to ¥6,448,991.48, reflecting the company's commitment to enhancing traditional Chinese medicine product development[17]. - The company’s total sales expenses rose by 58.90% to ¥66,677,904.83, driven by an increase in sales personnel and promotional expenses[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,033[12]. Financial Management - The company has engaged in entrusted financial management with a total amount of 20,000,000 CNY, all of which is currently unexpired and has no overdue amounts[26]. - The funds for entrusted financial management are sourced from temporarily idle raised funds[26]. - There are no significant risks associated with the entrusted financial management, as there are no expected losses of principal or other impairment risks[26]. Corporate Activities - The company conducted multiple on-site research and communication activities with institutions during the reporting period, with dates including August 31, September 14, and September 21, 2018[26]. - The company plans to use part of the raised funds to increase capital in its wholly-owned subsidiary, Zhejiang Jingyuetang Pharmaceutical Co., Ltd.[19]. Non-Recurring Gains - The company reported non-recurring gains of ¥2,927,419.15, primarily from the disposal of idle assets and government subsidies[10].